Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By Manas Mishra
  
Sanofi logo at a skyscraper in Warsaw, Poland
• Source: Shutterstock

More from Clinical Trials

More from R&D